Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + envafolimab + gemcitabine-based chemotherapy for first-line advanced biliary tract cancer
ChiCTR2400080783Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, tucidinostat, gemcitabine and oxaliplatin in biliary cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Safety and Objective response rate. Started Apr 2023; status: recruiting.
02
Drugs
envafolimabtucidinostatgemcitabineoxaliplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400080783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080783.